Table 2. Associations between p53 mutational status and clinicopathological parameters.
|
p53 status
|
||||
|---|---|---|---|---|
| Clinical parameters | n | Wild-type (n=33) | Mutant (n=121) | P-value |
| Age (years) | ||||
| Median (range) | 154 | 50 (26–73) | 58 (35–83) | <0.001 |
| Tumour stage | ||||
| III | 126 | 30 | 96 | 0.201 |
| IV | 28 | 3 | 25 | |
| Tumour grade | ||||
| I/II | 42 | 18 | 24 | <0.001 |
| III | 112 | 15 | 97 | |
| Residual disease | ||||
| 0 | 110 | 26 | 84 | 0.285 |
| ⩽1 cm | 28 | 6 | 22 | |
| >1 cm | 16 | 1 | 15 | |
| Treatment response a | ||||
| Yes | 115 | 26 | 89 | 0.492 |
| No | 38 | 6 | 32 | |
a
Treatment failure was defined as primary progression or early recurrence within 6 months after termination of primary platinum-based chemotherapy. In one patient treatment response could not be determined due to short follow-up.